HCW Biologics Inc., a U.S.-based clinical-stage biopharmaceutical company, announced that it has developed a second-generation, pembrolizumab-based immune checkpoint inhibitor targeting solid tumors, including pancreatic and ovarian cancers. The company said that its proprietary TRBC platform allows construction of fusion molecules that simultaneously activate immune cells and promote their infiltration into tumors.
According to the company, preclinical studies indicate that the fusion molecules outperform pembrolizumab as a monotherapy in vitro and in humanized mouse models, demonstrating enhanced anti-tumor activity at well-tolerated dose levels. HCW Biologics claims that the therapy also neutralizes the immunosuppressive cytokine TGF-β in the tumor microenvironment, potentially improving immune checkpoint inhibitor efficacy.
The company said that the second-generation inhibitor could also have applications as a senomorphic therapy for removing senescent cells to treat age-related diseases. HCW Biologics will present results from IND-enabling studies at Nova Southeastern University in Fort Lauderdale, Florida, on September 12, 2025.
HCW Biologics focuses on developing immunotherapies for diseases promoted by chronic inflammation, including age-related and senescence-associated conditions. The company said that its TRBC platform has enabled the construction of over 50 immunotherapeutic molecules across multiple classes, some of which are undergoing further preclinical evaluation.
The company claims its innovations have the potential to improve cancer treatment outcomes and address a range of diseases linked to chronic inflammation.
